Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa

Affiliations

¹ Discovery Health, Johannesburg, South Africa.
² National Institute of Communicable Diseases, Johannesburg, South Africa.
³ Desmond Tutu HIV Foundation, Cape Town, South Africa.
⁴ South African Medical Research Council, Cape Town, South Africa glenda.gray@mrc.ac.za.

Shirley Collie et al. N Engl J Med. 2022.

. 2022 Feb 3;386(5):494-496.

doi: 10.1056/NEJMc2119270. Epub 2021 Dec 29.

¹ Discovery Health, Johannesburg, South Africa.
² National Institute of Communicable Diseases, Johannesburg, South Africa.
³ Desmond Tutu HIV Foundation, Cape Town, South Africa.
⁴ South African Medical Research Council, Cape Town, South Africa glenda.gray@mrc.ac.za.

No abstract available

References

1. Network for Genomic Surveillance in South Africa. SARS-CoV-2 sequencing update. December 3, 2021. (https://www.nicd.ac.za/wp-content/uploads/2021/12/Update-of-SA-sequencin...).
1. Pulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. December 2, 2021 (https://www.medrxiv.org/content/10.1101/2021.11.11.21266068v2). preprint. - DOI - PMC - PubMed
1. Centers for Disease Control and Prevention. Science brief: evidence used to update the list of underlying medical conditions associated with higher risk for severe COVID-19. October 14, 2021. (https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/underly...). - PubMed
1. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant. N Engl J Med 2021;385:585-594. - PMC - PubMed
1. Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet 2021;398:2093-2100. - PMC - PubMed